Paper · 16636895
Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F and 6 others. Breast Cancer Res Treat, 2006. Cited by 98 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Papers, record 16636895. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16636895
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Carcinoma | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Receptors, Estrogen | Major topic |
| Syndecan-1 | Major topic |
| Syndecan-4 | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Biomarkers, Tumor | |
| Female | |
| Heparan Sulfate Proteoglycans | |
| Humans | |
| Ki-67 Antigen | |
| Middle Aged | |
| Time Factors |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01-CA107012 | NCI NIH HHS | United States | R01CA107012 | PubMed and NIH |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 98 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,694,191 | Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40694191 | PubMed |
| 40,437,501 | Reprogramming FGF1 from the natural growth factor to the engineered heparan sulphate biosensor. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40437501 | PubMed |
| 40,066,261 | Comprehensive investigation of proteoglycan gene expression in breast cancer: Discovery of a unique proteoglycan gene signature linked to the malignant phenotype. | Proteoglycan Res | 2025 | https://conductscience.org/library/papers/40066261 | PubMed |
| 39,568,121 | Decreased expression of Syndecan- 1 (CD138) in the endometrium of adenomyosis patients suggests a potential pathogenetic role. | Acta Obstet Gynecol Scand | 2025 | https://conductscience.org/library/papers/39568121 | PubMed |
| 37,762,403 | The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762403 | PubMed |
| 37,155,874 | Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37155874 | PubMed |
| 36,980,680 | Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980680 | PubMed |
| 36,725,112 | Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential. | Adv Cancer Res | 2023 | https://conductscience.org/library/papers/36725112 | PubMed |
| 35,812,066 | Eltrombopag binds SDC4 directly and enhances MAPK signaling and macropinocytosis in cancer cells. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35812066 | PubMed |
| 35,584,326 | Targeting syndecan-1: new opportunities in cancer therapy. | Am J Physiol Cell Physiol | 2022 | https://conductscience.org/library/papers/35584326 | PubMed |
1 to 10 of 60
See all 60 cited byGenes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDH1 | 999 | PubTator's text mining | https://conductscience.org/library/genes/999 | NCBI Gene |
| ESR1 | 2,099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| GPC1 | 2,817 | PubTator's text mining | https://conductscience.org/library/genes/2817 | NCBI Gene |
| PGR | 5,241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| SDC1 | 6,382 | PubTator's text mining | https://conductscience.org/library/genes/6382 | NCBI Gene |
| SDC4 | 6,385 | PubTator's text mining | https://conductscience.org/library/genes/6385 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16636895
GET https://conductscience.org/api/papers/v1/16636895/cited_by?page=2